Pharmerica Corporation (PMC) Set to Announce Quarterly Earnings on Tuesday

Pharmerica Corporation (NYSE:PMC) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, November 7th. Analysts expect the company to announce earnings of $0.49 per share for the quarter.

Pharmerica Corporation (NYSE:PMC) last issued its quarterly earnings data on Wednesday, August 2nd. The company reported $0.47 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.47. Pharmerica Corporation had a net margin of 1.05% and a return on equity of 10.94%. The firm had revenue of $592.00 million for the quarter, compared to analysts’ expectations of $592.96 million. During the same quarter in the prior year, the business earned $0.47 EPS. The business’s quarterly revenue was up 13.9% on a year-over-year basis. On average, analysts expect Pharmerica Corporation to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Pharmerica Corporation (NYSE:PMC) opened at $29.15 on Friday. Pharmerica Corporation has a one year low of $19.35 and a one year high of $29.50. The company has a quick ratio of 1.79, a current ratio of 2.57 and a debt-to-equity ratio of 0.75. The firm has a market cap of $907.12, a P/E ratio of 15.26, a PEG ratio of 1.27 and a beta of 0.82.

PMC has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Pharmerica Corporation from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a research note on Wednesday, September 27th. ValuEngine upgraded shares of Pharmerica Corporation from a “hold” rating to a “buy” rating in a research note on Tuesday, October 31st. Credit Suisse Group cut shares of Pharmerica Corporation from an “outperform” rating to a “neutral” rating and raised their target price for the stock from $29.00 to $29.25 in a research note on Friday, August 4th. They noted that the move was a valuation call. UBS AG restated a “neutral” rating and set a $29.25 target price (up previously from $26.00) on shares of Pharmerica Corporation in a research note on Thursday, August 3rd. Finally, KeyCorp cut shares of Pharmerica Corporation to an “overweight” rating in a research note on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. Pharmerica Corporation has an average rating of “Hold” and a consensus price target of $30.50.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at

About Pharmerica Corporation

Earnings History for Pharmerica Corporation (NYSE:PMC)

What are top analysts saying about Pharmerica Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pharmerica Corporation and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit